SCHEMBL5185688

SCHEMBL5185688

COC(=O)C(=NO)c1ccco1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
KMT2A Q03164 3/20 0.46
RAB9A P51151 6/20 0.46
NPC1 O15118 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
POLB P06746 3/20 0.45
MAOB P27338 1/20 0.44
TP53 P04637 1/20 0.44
MAPK1 P28482 1/20 0.43
PTPN1 P18031 1/20 0.43
LMNA P02545 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PSMD14 O00487 1/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8170511 1.00 CES2 (0.52) CES2CES1KMT2ARAB9ANPC1
SCHEMBL5185682 1.00 CES2 (0.52) CES2CES1KMT2ARAB9ANPC1
SCHEMBL20863020 0.86 CES2 (0.52) CES2CES1KMT2ARAB9ANPC1
SCHEMBL17426488 0.85 CES2 (0.50) CES2CES1KMT2ARAB9ANPC1
SCHEMBL5217865 0.85 CES2 (0.50) CES2CES1KMT2ARAB9ANPC1
SCHEMBL5217871 0.85 CES2 (0.50) CES2CES1KMT2ARAB9ANPC1
SCHEMBL6932527 0.80 SMN1; SMN2 (0.47) CES2CES1KMT2ARAB9ANPC1
SCHEMBL7199956 0.79 CES2 (0.52) CES2CES1KMT2ARAB9APOLB
SCHEMBL3275078 0.79 CES2 (0.52) CES2CES1KMT2ARAB9APOLB
SCHEMBL14577781 0.79 CES2 (0.52) CES2CES1KMT2ARAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288549-B2 Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents AVENTIS PHARMA S.A. (FR) 2007-10-30 US disclosed
US-20050245505-A1 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents ENTASIS THERAPEUTICS LIMITED (GB) 2005-11-03 US disclosed
US-6048852-A BACTERICIDES SMITHKLINE BEECHAM P.L.C. (GB) 2000-04-11 US disclosed
EP-0900197-A1 BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1999-03-10 EP disclosed
WO-1997030027-A1 BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1997-08-21 WO disclosed
US-4509970-A Substituted phenylphosphinyloxy- and phosphinylthio-iminocarboxylates useful for the control of weeds ZOECON CORPORATION (US) 1985-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245505-A1 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents FDPS, MRPL21, DHPS CES2 2421/4885CES1 3068/4885KMT2A 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.